469 related articles for article (PubMed ID: 15286803)
1. Cancer cachexia is regulated by selective targeting of skeletal muscle gene products.
Acharyya S; Ladner KJ; Nelsen LL; Damrauer J; Reiser PJ; Swoap S; Guttridge DC
J Clin Invest; 2004 Aug; 114(3):370-8. PubMed ID: 15286803
[TBL] [Abstract][Full Text] [Related]
2. NF-kappaB-induced loss of MyoD messenger RNA: possible role in muscle decay and cachexia.
Guttridge DC; Mayo MW; Madrid LV; Wang CY; Baldwin AS
Science; 2000 Sep; 289(5488):2363-6. PubMed ID: 11009425
[TBL] [Abstract][Full Text] [Related]
3. Biomedicine. Protein loss in cancer cachexia.
Tisdale MJ
Science; 2000 Sep; 289(5488):2293-4. PubMed ID: 11041796
[No Abstract] [Full Text] [Related]
4. Cachexia in cancer--zeroing in on myosin.
Chamberlain JS
N Engl J Med; 2004 Nov; 351(20):2124-5. PubMed ID: 15537911
[No Abstract] [Full Text] [Related]
5. Adaptation of the ubiquitin-proteasome proteolytic pathway in cancer cachexia.
Attaix D; Combaret L; Tilignac T; Taillandier D
Mol Biol Rep; 1999 Apr; 26(1-2):77-82. PubMed ID: 10363651
[TBL] [Abstract][Full Text] [Related]
6. Chemotherapy inhibits skeletal muscle ubiquitin-proteasome-dependent proteolysis.
Tilignac T; Temparis S; Combaret L; Taillandier D; Pouch MN; Cervek M; Cardenas DM; Le Bricon T; Debiton E; Samuels SE; Madelmont JC; Attaix D
Cancer Res; 2002 May; 62(10):2771-7. PubMed ID: 12019153
[TBL] [Abstract][Full Text] [Related]
7. Valproic acid attenuates skeletal muscle wasting by inhibiting C/EBPβ-regulated atrogin1 expression in cancer cachexia.
Sun R; Zhang S; Hu W; Lu X; Lou N; Yang Z; Chen S; Zhang X; Yang H
Am J Physiol Cell Physiol; 2016 Jul; 311(1):C101-15. PubMed ID: 27122162
[TBL] [Abstract][Full Text] [Related]
8. Development of an in-vitro model system to investigate the mechanism of muscle protein catabolism induced by proteolysis-inducing factor.
Gomes-Marcondes MC; Smith HJ; Cooper JC; Tisdale MJ
Br J Cancer; 2002 May; 86(10):1628-33. PubMed ID: 12085214
[TBL] [Abstract][Full Text] [Related]
9. STAT3 activation in skeletal muscle links muscle wasting and the acute phase response in cancer cachexia.
Bonetto A; Aydogdu T; Kunzevitzky N; Guttridge DC; Khuri S; Koniaris LG; Zimmers TA
PLoS One; 2011; 6(7):e22538. PubMed ID: 21799891
[TBL] [Abstract][Full Text] [Related]
10. Mechanism of attenuation of skeletal muscle protein catabolism in cancer cachexia by eicosapentaenoic acid.
Whitehouse AS; Smith HJ; Drake JL; Tisdale MJ
Cancer Res; 2001 May; 61(9):3604-9. PubMed ID: 11325828
[TBL] [Abstract][Full Text] [Related]
11. JAK/STAT3 pathway inhibition blocks skeletal muscle wasting downstream of IL-6 and in experimental cancer cachexia.
Bonetto A; Aydogdu T; Jin X; Zhang Z; Zhan R; Puzis L; Koniaris LG; Zimmers TA
Am J Physiol Endocrinol Metab; 2012 Aug; 303(3):E410-21. PubMed ID: 22669242
[TBL] [Abstract][Full Text] [Related]
12. A new model of cancer cachexia: contribution of the ubiquitin-proteasome pathway.
Lazarus DD; Destree AT; Mazzola LM; McCormack TA; Dick LR; Xu B; Huang JQ; Pierce JW; Read MA; Coggins MB; Solomon V; Goldberg AL; Brand SJ; Elliott PJ
Am J Physiol; 1999 Aug; 277(2):E332-41. PubMed ID: 10444430
[TBL] [Abstract][Full Text] [Related]
13. Myosin heavy chain is not selectively decreased in murine cancer cachexia.
Cosper PF; Leinwand LA
Int J Cancer; 2012 Jun; 130(11):2722-7. PubMed ID: 21796617
[TBL] [Abstract][Full Text] [Related]
14. Activation of the ATP-ubiquitin-proteasome pathway in skeletal muscle of cachectic rats bearing a hepatoma.
Baracos VE; DeVivo C; Hoyle DH; Goldberg AL
Am J Physiol; 1995 May; 268(5 Pt 1):E996-1006. PubMed ID: 7539218
[TBL] [Abstract][Full Text] [Related]
15. Manipulation of the ubiquitin-proteasome pathway in cachexia: pentoxifylline suppresses the activation of 20S and 26S proteasomes in muscles from tumor-bearing rats.
Combaret L; Rallière C; Taillandier D; Tanaka K; Attaix D
Mol Biol Rep; 1999 Apr; 26(1-2):95-101. PubMed ID: 10363654
[TBL] [Abstract][Full Text] [Related]
16. Metastatic cancers promote cachexia through ZIP14 upregulation in skeletal muscle.
Wang G; Biswas AK; Ma W; Kandpal M; Coker C; Grandgenett PM; Hollingsworth MA; Jain R; Tanji K; Lόpez-Pintado S; Borczuk A; Hebert D; Jenkitkasemwong S; Hojyo S; Davuluri RV; Knutson MD; Fukada T; Acharyya S
Nat Med; 2018 Jun; 24(6):770-781. PubMed ID: 29875463
[TBL] [Abstract][Full Text] [Related]
17. Tumor necrosis factor-alpha inhibits myogenic differentiation through MyoD protein destabilization.
Langen RC; Van Der Velden JL; Schols AM; Kelders MC; Wouters EF; Janssen-Heininger YM
FASEB J; 2004 Feb; 18(2):227-37. PubMed ID: 14769817
[TBL] [Abstract][Full Text] [Related]
18. Weight gain does not preclude increased ubiquitin conjugation in skeletal muscle: an exploratory study in tumor-bearing mice.
Jatoi A; Cleary MP; Tee CM; Nguyen PL
Ann Nutr Metab; 2001; 45(3):116-20. PubMed ID: 11423703
[TBL] [Abstract][Full Text] [Related]
19. Pantoprazole blocks the JAK2/STAT3 pathway to alleviate skeletal muscle wasting in cancer cachexia by inhibiting inflammatory response.
Guo D; Wang C; Wang Q; Qiao Z; Tang H
Oncotarget; 2017 Jun; 8(24):39640-39648. PubMed ID: 28489606
[TBL] [Abstract][Full Text] [Related]
20. Muscle oxidative capacity during IL-6-dependent cancer cachexia.
White JP; Baltgalvis KA; Puppa MJ; Sato S; Baynes JW; Carson JA
Am J Physiol Regul Integr Comp Physiol; 2011 Feb; 300(2):R201-11. PubMed ID: 21148472
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
